Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

Orazio Caffo, Cinzia Ortega, Franco Nolè, Donatello Gasparro, Claudia Mucciarini, Michele Aieta, Vittorina Zagonel, Roberto Iacovelli, Ugo De Giorgi, Gaetano Facchini, Antonello Veccia, Erica Palesandro, Elena Verri, Sebastiano Buti, Giorgia Razzini, Giovanni Bozza, Marco Maruzzo, Chiara Ciccarese, Giuseppe Schepisi, Sabrina Rossetti, Francesca Maines, Stefania Kinspergher, Lucia Fratino, Paola Ermacora, Maurizio Nicodemo, Monica Giordano, Donata Sartori, Daniela Scapoli, Roberto Sabbatini, Giovanni Lo Re, Franco Morelli, Alessandro D’Angelo, Isabella Vittimberga, Paolo Lippe, Francesco Carrozza, Caterina Messina, Luca Galli, Francesca Valcamonico, Camillo Porta, Giovanni Pappagallo, Massimo Aglietta

Open source

DOI: 10.1016/j.ejca.2021.06.016
Published: 2021-09
Container: European Journal of Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2021.06.016,
  title = {Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial},
  author = {Orazio Caffo and Cinzia Ortega and Franco Nolè and Donatello Gasparro and Claudia Mucciarini and Michele Aieta and Vittorina Zagonel and Roberto Iacovelli and Ugo De Giorgi and Gaetano Facchini and Antonello Veccia and Erica Palesandro and Elena Verri and Sebastiano Buti and Giorgia Razzini and Giovanni Bozza and Marco Maruzzo and Chiara Ciccarese and Giuseppe Schepisi and Sabrina Rossetti and Francesca Maines and Stefania Kinspergher and Lucia Fratino and Paola Ermacora and Maurizio Nicodemo and Monica Giordano and Donata Sartori and Daniela Scapoli and Roberto Sabbatini and Giovanni Lo Re and Franco Morelli and Alessandro D’Angelo and Isabella Vittimberga and Paolo Lippe and Francesco Carrozza and Caterina Messina and Luca Galli and Francesca Valcamonico and Camillo Porta and Giovanni Pappagallo and Massimo Aglietta},
  year = {2021},
  journal = {European Journal of Cancer},
  doi = {10.1016/j.ejca.2021.06.016},
  url = {https://doi.org/10.1016/j.ejca.2021.06.016}
}

RIS

TY  - JOUR
TI  - Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
AU  - Orazio Caffo
AU  - Cinzia Ortega
AU  - Franco Nolè
AU  - Donatello Gasparro
AU  - Claudia Mucciarini
AU  - Michele Aieta
AU  - Vittorina Zagonel
AU  - Roberto Iacovelli
AU  - Ugo De Giorgi
AU  - Gaetano Facchini
AU  - Antonello Veccia
AU  - Erica Palesandro
AU  - Elena Verri
AU  - Sebastiano Buti
AU  - Giorgia Razzini
AU  - Giovanni Bozza
AU  - Marco Maruzzo
AU  - Chiara Ciccarese
AU  - Giuseppe Schepisi
AU  - Sabrina Rossetti
AU  - Francesca Maines
AU  - Stefania Kinspergher
AU  - Lucia Fratino
AU  - Paola Ermacora
AU  - Maurizio Nicodemo
AU  - Monica Giordano
AU  - Donata Sartori
AU  - Daniela Scapoli
AU  - Roberto Sabbatini
AU  - Giovanni Lo Re
AU  - Franco Morelli
AU  - Alessandro D’Angelo
AU  - Isabella Vittimberga
AU  - Paolo Lippe
AU  - Francesco Carrozza
AU  - Caterina Messina
AU  - Luca Galli
AU  - Francesca Valcamonico
AU  - Camillo Porta
AU  - Giovanni Pappagallo
AU  - Massimo Aglietta
PY  - 2021
JO  - European Journal of Cancer
DO  - 10.1016/j.ejca.2021.06.016
UR  - https://doi.org/10.1016/j.ejca.2021.06.016
ER  -

APA

Caffo, O., Ortega, C., Nolè, F., Gasparro, D., Mucciarini, C., Aieta, M., Zagonel, V., Iacovelli, R., Giorgi, U. D., Facchini, G., Veccia, A., Palesandro, E., Verri, E., Buti, S., Razzini, G., Bozza, G., Maruzzo, M., Ciccarese, C., Schepisi, G., Rossetti, S., Maines, F., Kinspergher, S., Fratino, L., Ermacora, P., Nicodemo, M., Giordano, M., Sartori, D., Scapoli, D., Sabbatini, R., Re, G. L., Morelli, F., D’Angelo, A., Vittimberga, I., Lippe, P., Carrozza, F., Messina, C., Galli, L., Valcamonico, F., Porta, C., Pappagallo, G., & Aglietta, M. (2021). Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2021.06.016

Source records

crossref · retrieved 2026-11-11T01:51:04.321Z